Accuitis is a startup based in the United States.
Accuitis develops therapeutic drugs that protect and restore healthy cellular function in neurodegenerative diseases such as Alzheimer's, Parkinson's, and methamphetamine addiction by targeting mitochondrial SIRT3 expression.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.